PCSK7、PNPLA3与TM6SF2变异增加遗传性血色病肝硬化风险
在1319例来自六个欧洲国家的C282Y纯合子中,评估PCSK7、PNPLA3、TM6SF2等基因变异与肝硬化风险的关联。固定效应荟萃分析显示,PCSK7:rs236918、PNPLA3:rs738409和TM6SF2:rs58542926均显著增加肝硬化风险,三者合并的人群归因分数为24.0%。
要点
- PCSK7:rs236918、PNPLA3:rs738409和TM6SF2:rs58542926与C282Y纯合子肝硬化风险显著相关。
- 三种变异合并的人群归因分数为24.0%,提示联合检测有助于风险分层。
- 在具有肝脏组织学资料的亚组中,上述关联仍然显著。
核心结论
- PCSK7:rs236918与C282Y纯合子肝硬化风险的关联在更大样本中得到证实。
- PNPLA3:rs738409和TM6SF2:rs58542926被确立为显著的额外危险因素。
- 对C282Y纯合子进行更详细的基因检测有助于风险分层并指导未来管理。
研究设计与样本
- 研究纳入来自六个欧洲国家的1319例C282Y纯合子,其中171例(13.0%)患有肝硬化。
- 对PCSK7、PNPLA3、TM6SF2、MBOAT7和HSD17B13变异进行基因分型,并调整年龄和性别。
- 采用固定效应荟萃分析合并各国调整后的汇总数据。
- 事后在具有肝脏组织学资料的131例(76.6%)病例和299例(26.0%)对照中进行关联检验。
主要发现
- PCSK7:rs236918与肝硬化风险显著相关(OR=1.52,95%CI 1.06-2.19,P=0.022,I²=0%)。
- PNPLA3:rs738409与肝硬化风险显著相关(OR=1.60,95%CI 1.22-2.11,P=7.37×10⁻⁴,I²=45.5%)。
- TM6SF2:rs58542926与肝硬化风险显著相关(OR=1.94,95%CI 1.28-2.95,P=1.86×10⁻³,I²=0%)。
- 在具有肝脏组织学资料的亚组中,上述关联仍然显著。
关键数值与推荐
- PCSK7:rs236918的人群归因分数为5.6%。
- PNPLA3:rs738409的人群归因分数为13.8%。
- TM6SF2:rs58542926的人群归因分数为6.5%。
- 三种变异合并携带的人群归因分数为24.0%。
临床怎么用
- 对C282Y纯合子可考虑检测PCSK7、PNPLA3和TM6SF2变异以辅助肝硬化风险分层。
- 联合携带三种变异者肝硬化风险更高,或需更密切监测。
局限性
- 事后组织学亚组分析仅纳入部分病例和对照。
- 研究仅涉及欧洲人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cirrhosis develops in <10% of individuals homozygous for the C282Y variant in the homeostatic iron regulator (HFE) gene. Carriage of PCSK7:rs236918 is associated with an increased risk of cirrhosis in this population. AIM: To determine if genetic variants significantly associated with the risk of alcohol- and NAFLD-related cirrhosis also modulate the cirrhosis risk in C282Y homozygotes. METHODS: Variants in PCSK7, PNPLA3, TM6SF2, MBOAT7 and HSD17B13 were genotyped in 1319 C282Y homozygotes, from six European countries, of whom 171 (13.0%) had cirrhosis. Genotypic and allelic associations with the risk for developing cirrhosis were assessed, adjusting for age and sex. Fixed effects meta-analyses of the adjusted summary data for each country were performed. Post hoc association testing was undertaken in the 131 (76.6%) cases and 299 (26.0%) controls with available liver histology. RESULTS: Significant associations were observed between PCSK7:rs236918 (OR = 1.52 [95% CI 1.06-2.19]; P = 0.022; I2 = 0%); PNPLA3:rs738409 (OR = 1.60 [95% CI 1.22-2.11]; P = 7.37 × 10-4 ; I2 = 45.5%) and TM6SF2:rs58542926 (OR = 1.94 [95% CI 1.28-2.95]; P = 1.86 × 10-3 ; I2 = 0%) and the cirrhosis risk in C282Y homozygotes. These findings remained significant in the subpopulation with available liver histology. The population-attributable fractions were 5.6% for PCSK7:rs236918, 13.8% for PNPLA3:rs738409, 6.5% for TM6SF2:rs58542926 and 24.0% for carriage of all three variants combined. CONCLUSIONS: The risk of cirrhosis associated with carriage of PCSK7:rs236918 was confirmed in this much larger population of C282Y homozygotes. In addition, PNPLA3:rs738409 and TM6SF2:rs58542926 were established as significant additional risk factors. More detailed genetic testing of C282Y homozygotes would allow risk stratification and help guide future management.
引用
- Buch S, Sharma A, Ryan E, et al. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Aliment Pharmacol Ther. 2021. PMID: 33565643. doi:10.1111/apt.16252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。